Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

Authors:

Abstract
Purpose: Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with β-particle–emitting isotopes such as 90Y or 177Lu has been a promising treatment strategy for metastasized neuroendocrine tumors. Although remission can be accomplished in a high percentage of neuroendocrine tumors, some tumors do not respond to this treatment. α-Emitting isotopes—such as the 10-day half-life α-emitting generator nuclide Actinum-225 (225Ac)—are characterized by extremely high cytotoxic activity on the cellular level, and may be superior in the treatment of neuroendocrine tumors not responding to PRRT using β-emitting isotopes.

This publication has 17 references indexed in Scilit: